Review Article

Updated and New Perspectives on Diagnosis, Prognosis, and Therapy of Malignant Pheochromocytoma/Paraganglioma

Gabriele Parenti,1 Benedetta Zampetti,2 Elena Rapizzi,2,3 Tonino Ercolino,1 Valentino Giachè,2 and Massimo Mannelli2,3

1 Endocrinology Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy
2 Department of Clinical Pathophysiology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy
3 Istituto Toscano Tumori, Via Taddeo Alderotti 26N, 50139 Florence, Italy

Correspondence should be addressed to Massimo Mannelli, m.mannelli@dfc.unifi.it

Received 30 April 2012; Accepted 5 June 2012

Copyright © 2012 Gabriele Parenti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Malignant pheochromocytomas/paragangliomas are rare tumors with a poor prognosis. Malignancy is diagnosed by the development of metastases as evidenced by recurrences in sites normally devoid of chromaffin tissue. Histopathological, biochemical, molecular and genetic markers offer only information on potential risk of metastatic spread. Large size, extraadrenal location, dopamine secretion, SDHB mutations, a PASS score higher than 6, a high Ki-67 index are indexes for potential malignancy. Metastases can be present at first diagnosis or occur years after primary surgery. Measurement of plasma and/or urinary metanephrine, normetanephrine and metoxytyramine are recommended for biochemical diagnosis. Anatomical and functional imaging using different radionuclides are necessary for localization of tumor and metastases. Metastatic pheochromocytomas/paragangliomas is incurable. When possible, surgical debulking of primary tumor is recommended as well as surgical or radiosurgical removal of metastases. I-131-MIBG radiotherapy is the treatment of choice although results are limited. Chemotherapy is reserved to more advanced disease stages. Recent genetic studies have highlighted the main pathways involved in pheochromocytomas/paragangliomas pathogenesis thus suggesting the use of targeted therapy which, nevertheless, has still to be validated. Large cooperative studies on tissue specimens and clinical trials in large cohorts of patients are necessary to achieve better therapeutic tools and improve patient prognosis.

1. Introduction

Paragangliomas (PGLs) are rare neuroendocrine tumors that arise in sympathetic and parasympathetic paraganglia and derive from neural crest cells. Approximately 80–85% of these tumour arise from the adrenal medulla and are named pheochromocytomas (PCCs), whereas 15–20% are located in extra-adrenal chromaffin tissue and are referred to as secreting paragangliomas (sPGLs). The latter term is also used to describe tumors derived from parasympathetic tissue in the head and neck (HNPGGLs).

PCCs and abdominal sPGLs are usually catecholamine-producing tumours, whereas most of the HNPGGLs are non-functioning [1].

The majority of PGLs are sporadic, but recent data have demonstrated a high prevalence of hereditary forms (approximately 35%) [2]. Sporadic PGLs are usually diagnosed in patients older than 40–50 years, whereas hereditary forms are diagnosed in younger patients.

Malignancy is defined by presence of metastases, tumor spread in sites where chromaffin tissue is normally absent such as lymph nodes, liver, lungs, and bones. Malignant PGLs are extremely rare. An estimated incidence in USA in 2002 was 93 cases per 400 million persons [3].

Nearly 10% and 20% of PCCs and abdominal sPGLs, respectively, are malignant [4], whereas HNPGLs are usually benign [5].

2. Clinical Feature

The high variability in clinical presentation of PGLs is well known [6]. It depends on the variability in the biology of
these tumors which can express different catecholamine biosynthetic enzymes, secrete different vasoactive peptide (i.e., neuropeptide Y, adrenomedullin, or atrial natriuretic peptide) [7], present different symptoms related to tumor mass or present symptoms related to other organs involvement in syndromic forms.

Hypertension is the most common feature of PCCs and sPGL: it can be continuous, intermittent, and often paroxysmal in nature. Hypertensive crises are frequently associated with the classic triad of severe headache, palpitations, and diaphoresis. Other signs or symptoms such as dyspnea, weakness, arrhythmias, visual disturbances and metabolic effect such as glucose intolerance and weight loss are reported [1]. The cardiovascular complications (sudden death, myocardial infarction, heart failure, and cerebrovascular accidents) represent the most frequent causes of morbidity and mortality in these patients.

HNPGLs are usually clinically silent, but they can determine manifestations related to mass effect or infiltration of the adjacent structures. In such situations the presence of a palpable neck mass as well as pain, dysphagia, tinnitus, or cranial nerve palsies has been reported [8].

In addition to the abovementioned symptoms and signs, malignant PGLs may also present “systemic” symptoms (anorexia, fatigue, and weight loss) or clinical manifestations related to the metastatic disease such as pain in bones affected by metastatic spread. Malignant PGLs, being less-differentiated tumors with a less differentiated biosynthetic pathway, generally secrete noradrenaline and/or dopamine causing even milder cardiovascular symptoms and a subclinical picture [9]. Metastatic spread may occur at presentation or even after many years from primary surgery.

3. Diagnosis: Biochemistry

The recommended screening test for initial assessment of PGLs is the measurement of plasma free-metanephrines or urine-deconjugated differential metanephrines [10]. In fact in comparison to plasma or urine catecholamines and vanillmandelic acid, metanephrines show higher sensitivity, ranging around 98–99% [11, 12]. This is mainly related to their longer half-life and to their continuous production by the tumor where catecholamines are converted to metanephrines by the high methyltransferase activity of the chromaffin tissue [13].

The biochemical phenotype does not permit to differentiate malignant from benign PGLs.

PGLs exhibit different biochemical properties as PCCs mainly produce adrenaline, while sPGLs secrete noradrenaline. Malignant PCCs secrete predominantly noradrenaline [14], but due to an even less-differentiated catecholamine biosynthetic pathway, they may often produce mainly or exclusively dopamine [15]. Therefore, the presence of large predominantly noradrenaline-producing PGLs and increased levels of plasma dopamine or its metabolite methoxytyramine may suggest malignancy [11, 16].

Plasma chromogranin A (CgA), a protein stored and co-secreted with catecholamines, is often increased in functioning and nonfunctioning PGLs [17]. CgA shows a sensitivity of 83–89% for identifying PGLs, but it often shows false positive results because of liver or kidney failure or proton pump inhibitor therapy [18].

Malignancy is generally associated to very high plasma levels of CgA [11].

High plasma levels of neuron-specific enolase are sometimes found in patients with malignant PGLs [19, 20], while overexpression of secretogranin II and prohormone convertases I and II suggests a benign lesion [21].

4. Diagnosis: Anatomical and Functional Imaging

Anatomical imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) is useful as the first radiological approach in patients with PGLs. CT shows a sensitivity of 77–98% and a specificity of 29–92% in the localization of adrenal or extra-adrenal tumors. A slightly better accuracy (sensitivity 90–100% and specificity 50–100%) has been reported for MRI, especially for the detection of extra-adrenal disease [22].

PGLs are highly vascular tumors with a high intracellular water content and frequent intratumoral cystic lesions, which show a typical, but not diagnostic, high signal on T2-weighted imaging, and strong enhancement after contrast-agent administration. Nevertheless, in large tumors with hemorrhagic and/or necrotic areas (features often detected in malignant lesions), the signal intensity on T2-weighted images may be low [23].

Ultrasound imaging is of limited diagnostic yield but can be useful for the detection of HNPGLs [22, 24].

After “anatomical” imaging, a “functional” imaging is generally recommended. 131I or 123I-metaiodobenzylguanidine (MIBG) scintigraphy has been used extensively as a first-line nuclear medicine technique in evaluation of patients with PGLs. MIBG has chemical similarities to norepinephrine and is concentrated in chromaffin tissue, via the human norepinephrine transporter (hNET), that is expressed in most of chromaffin cells and it is normally responsible for catecholamines uptake [25].

123I-MIBG is superior to 131I-MIBG in terms of physical properties, quality of images, and sensitivity. 123I-MIBG scanning shows a sensitivity of 83–100% and a specificity of 95–100% [22]. The possibility to perform a whole-body study, may permit a better evaluation of extra-adrenal localization of the disease as well as of multiple tumors and/or metastatic sites [25]. The sensitivity of this technique in malignant PGLs may be lower as evidenced in situation highly associated with malignancy as in SDHB mutation carriers (see later) or patients with dopamine-secreting tumours which usually do not uptake MIBG [26].

In patients with negative MIBG scintigraphy, other tracers may be used. The expression of somatostatin receptors (SSTRs), especially SSTR 2, 3, and 5 on chromaffin cells, represents the rationale for the use of radiolabelled somatostatin analogues in localization of these tumors. Indium-111-DTPA-octreotide (111In-pentetreotide) is the tracer most commonly used; it is of limited value in benign PCCs, but it may be
useful in detecting extra-adrenal disease as well as MIBG-negative metastases. In fact, a sensitivity near to 90% has been reported for localizing sPGLs, HNPGLs, or malignant PCCs [22, 27].

Somatostatin analogues labelled with gallium-68 can be used in PET imaging; 68Ga-DOTATOC (DOTA0-D-Phe1-Tyr3-octreotide) has shown a better sensitivity than 111In-pentetreotide in the detection of neuroendocrine tumors especially in detecting small lesions or neoplasms bearing only a low density of SSTR. Moreover, it permits a better identification of metastases located in the lung or in the skeleton. In relation to PGLs, this tracer seems superior to 18F-labelled fluoro-deoxy-glucose (18F-FDG) in detecting malignant PCCs and sPGLs [28–30].

Radiolabelled dopamine (DA) or dihydroxyphenylalanine (DOPA) which are transported in to chromaffin cells by hNET, may be used as tracers in positron emission tomography (PET) imaging. PET with 6-18F-fluoro-DA can detect metastatic PCCs with better sensitivity than 131I-MIBG [31], whereas PET with 6-18F-fluoroDOPA is superior in imaging sPGLs and HNPGLs [32]. However, as for MIBG, these tracers show a relative low sensitivity (70–88%) in PGLs associated with SDHB gene mutations. In such conditions PET with 18F-FDG shows a higher sensitivity (97–100%) [33]; this PET scanning is useful in identifying glucose-avid metastatic lesions, particularly if they are MIBG-negative [34].

Finally PET imaging with 11C-hydroxyephedrine has provided high sensitivity and specificity (92 and 100%, resp.) in the detection of PGLs, but the small number of patients studied makes not possible to draw conclusions on its utility [35].

5. Diagnosis: Histopathologic and Molecular Markers

Despite the increasing availability of molecular diagnostic and prognostic markers, it remains difficult to predict, on the basis of histological findings, whether an apparently benign PGL will develop in a malignant tumor. From a prognostic point of view, only relative risk factors can be taken into account. In general PGLs larger than 5 cm with necrotic areas as well as extra-adrenal tumors carry a higher risk of malignancy than neoplasms that are small or located in the adrenal. Several scoring systems considering invasion, histologic growth patterns, cytologic features, or mitotic activity have been proposed to calculate the risk of malignancy [36–38]. One of the most utilized score is “Pheochromocytoma of the Adrenal gland Scales Score (PASS),” proposed by Thompson on 2002. Table 1 reports the items and their values which are necessary to calculate the PASS. A PASS score ≥4 was at first considered suggestive for a biological aggressive behaviour, but a later study revealed that all malignant PCCs had a PASS >6 [39]. On the basis of these results a PASS score <4 or >6 suggest benign and malignant lesions respectively, whereas a value between 4 and 6 suggests an intermediate risk. In any event, as none of the available scores predicts malignant development unequivocally, after the removal of an isolated primary PGL, a followup of the patient is recommended in order to reveal early disease recurrence. Between histological features, high cellularity and particularly the presence of tumor necrosis are considered potential indicators of malignancy.

Further information can derive from the evaluation of specific molecular markers. Several malignancy tissue markers such as cyclooxygenase-2, secretogranin II-derived peptide, N-cadherin, vascular endothelial growth factor (VEGF), endothelin receptor type A (ETA), and type B (ETB) and telomerase have been identified. In particular telomerase, which is a ribonucleoprotein complex that includes the telomerase RNA component, the telomerase-associated protein (TP1), the telomerase catalytic subunit (hTERT), and the heat shock protein 90 (HSP90) seem to be closely related to the malignant potential of PGLs. In fact an upregulation of hTERT, HSP90, and telomerase activity has been evidenced in malignant cells of PCCs [40].

The Ki-67 nuclear antigen represents another potential molecular marker which has been associated with more aggressive cancers. A Ki-67 index >3% is considered a useful parameter predicting malignant potential [41].

Another promising marker predicting metastatic potential seems the transcription factor SNAIL. Positive immunostaining has been found significantly higher in metastatic than benign PGLs [42, 43].

Novel biomarkers are recently being identified by microRNA expression profiling studies. Micro-RNA is small single-strand (~22 bp), nonprotein coding RNA fragments, which are able to negatively regulate protein expression by either cleavage or translational repression of mRNA [44]. Recently, Meyer-Rochow, and colleagues [45] investigated 12 malignant, 12 benign tumors, and 5 healthy adrenal medulla samples. They found that miR-483-5p was overexpressed, while miR15a and miR-16, which are involved in proliferation and apoptosis, were downregulated in malignant compared to benign tumors. MicroRNA expression is tissue specific, and it has been demonstrated to be altered in several other human tumors. For these reasons, they can be of great

| Table 1: Pheochromocytoma of the adrenal gland scoring scale (PASS) [38]. |
|-----------------|-----------------|
| Items                        | Value |
| Nuclear hyperchromasia    | 1     |
| Profound nuclear pleomorphism | 1     |
| Capsular invasion         | 1     |
| Vascular invasion         | 1     |
| Extension into adipose tissue | 2     |
| Atypical mitotic figures  | 2     |
| Greater than 3 of 10 mitotic figures high-power field | 2 |
| Tumor cell spindling       | 2     |
| Cellular monotony         | 2     |
| High cellularity           | 2     |
| Central or confluent tumor necrosis | 2 |
| Large nests or diffuse growth (>10% of tumor volume) | 2 |

Total 20
relevance for the establishment of malignancy, but further investigations in larger cohorts of patients are necessary to confirm these encouraging results.

6. Diagnosis: Genetic Aspects

Until 2000, only 10% of PGLs were considered of genetic origin and linked to hereditary syndromes: von Hippel Lindau disease (VHL), multiple endocrine neoplasia type 2 (MEN2) and neurofibromatosis type 1 (NF1), due respectively to a germ line mutation in tumor-suppressor gene VHL [46, 47] and protooncogene RET [48–52] and tumor-suppressor gene NF1 [53].

In the last years it has been demonstrated that about 30% of the apparently sporadic PGLs are due to a germ-line mutation in one of the susceptibility genes [54]. This group of genes includes those encoding the four subunits (A, B, C, and D) of the succinate dehydrogenase (SDH) [55–58], the recently identified gene SDHAF2, which is responsible for the flavination of the SDHA subunit [59], and the very recently discovered TMEM127 [60] and tumor-suppressor gene NF1 [53].

In Table 2, the correlations between gene mutations and clinical phenotype are listed. It is evident that SDHx mutations are associated with a higher risk of malignancy, while RET and NF1 mutations are associated with a lower risk.

| Syndrome       | Gene     | PCCs (%) | Sympathetic PGL | Parasympathetic PGL | Bilateral/multifocal neoplasia | Malignancy (%) |
|----------------|----------|----------|-----------------|---------------------|-------------------------------|----------------|
| MEN 2A         | RET      | ~50      | Very rare       | Extremely rare       | +                             | <5             |
| MEN 2B         | RET      | ~50      | Very rare       | Extremely rare       | +                             | <5             |
| VHL            | VHL      | 10–20    | +               | Rare                | +                             | 5              |
| NF1            | NF1      | 5        | −               | −                   | −                             | 11             |
| PGL1           | SDHD     | +        | +               | +                   | +                             | ~5             |
| PGL2           | SDHA2    | −        | −               | +                   | +                             | Not known      |
| PGL3           | SDHC     | Rare     | +               | Rare                | −                             | Not known      |
| PGL4           | SDHB     | Rare     | +               | Rare                | +                             | ~40            |
| PGL5           | SDHA     | −        | +               | −                   | Not known                     | Not known      |
| TMEM127 mutation carriers | TMEM127 | 100      | −               | −                   | +                             | ~5             |
| MAX mutation carriers | MAX    | 100      | +               | Extremely rare       | +                             | ~10            |

PCCs: pheochromocytomas; PGL: paragangliomas; +: present; −: absent.

A guide for a more quick and cost-effective genetic screening (Table 2) [63].

Genetic analysis has also permitted to predict the malignancy risk which is higher for SDHB mutation carriers.

Furthermore, by studying tumor transcription profile, sporadic as well as hereditary PGLs have been divided into two main clusters linked to two different signalling pathways [64]: the first cluster contains all VHL- and SDHx-mutated tumors and is associated with angiogenesis, hypoxia, and reduced oxidative response [65], while the second cluster contains all RET- and NF1-mutated tumors and is associated with abnormal activation of kinase-signaling pathways, such as RAS/RAF/MAPK and PI3K/AKT/mTOR [66–69]; also TMEM127 [60] and MAX [61] mutated tumors have been associated to the activation of mTOR-signaling pathway. These data have increased overall knowledge on molecular defects in PGLs and could be used for development of new effective molecular-targeted therapies.

7. Therapy: Surgery

The main goal of surgical treatment is represented by the removal of primary tumor and, when possible, the resection of local and distant metastases. The overall 5-year survival rate of patients with malignant PGLs varies between 34% and 60%. The survival rate may depend upon sites of metastatic lesions. In fact, patients with liver or lung metastases tend to have a worse prognosis (<5 years) than patients with isolated bone lesions [2].

The preoperative management with alpha blockade and fluid administration, essential in order to avoid surgical complications (i.e., hypertensive crisis arrhythmias) and/or postsurgical complications (i.e., hypotension), has to be performed in all patients [1].

Laparoscopic removal of intra-adrenal and extra-adrenal PGLs is the preferred surgical technique, but, in case of large tumors with a high risk of malignancy, a transabdominal approach should be considered. In such circumstances total adrenalectomy with resection of locoregional lymph nodes or complete excision of PGLs together with the removal of
distant metastases is recommended [70]. In case of malignant disease surgery alone is seldom curative, but surgical debulking of the tumors is regarded as a mainstay of palliative therapy. In fact, it permits to reduce local or systemic symptoms related to catecholamine secretion, it improves response to other therapeutic approaches and it may prevent further diffusion of the tumors. Pre-operative injection of $^{123}$I-MIBG and intraoperative application of a γ-probe may permit the localization of lesions that are not evidenced by other imaging techniques [71].

In the presence of liver metastases arterial embolisation or chemoembolisation may provide transient response, but in such circumstances radiofrequency ablation has become the preferred choice [72]. In the next future, the rapidly evolving stereotaxic radiotherapic techniques will probably represent valid alternative tools for metastasis removal.

8. Therapy: Radiometabolic Treatment and External Radiotherapy

Radionuclide treatment may be considered in patients with metastatic disease and no resectable lesions. It can be performed using beta-emitting isotopes coupled with MIBG or somatostatin analogue.

$^{131}$I-MIBG was used in the treatment of malignant PCC for the first time in 1984 [73]. Patients are selected by the evidence of significant radioisotope uptake on diagnostic scintigraphy with $^{123}$I-MIBG or $^{131}$I-MIBG (>1% uptake of the injected dose). Single or fractionated doses as well as variable dosage (200–1400 mCi) have been proposed [74, 75]. About 60% of metastatic sites are $^{131}$I-MIBG avid [76]. In general better responses are seen in patients with limited disease and in patients with soft-tissue metastases than in patients with bone metastases [77]. This treatment is well tolerated, and the main side effects are represented by transient leucopenia and thrombocytopenia, whereas severe bone marrow toxicity (associated with high-dose regimen) is rarely seen.

However treatment with $^{131}$I-MIBG is not curative in most patients; therefore, other forms of therapy need to be considered.

The presence of SSTR in PGLs has allowed treatment with radiolabelled somatostatin analogues. The most commonly used are Yttrium-90-DOTATOC (Y-DOTA-TOC) and Lutetium-177-DOTA$^\text{6}$-Tyr$^3$-octreotate (Lu-DOTATE) [75, 78, 79]. As for $^{131}$I-MIBG, patients are selected by the demonstration of high tumor uptake at scintigraphy. The latter is usually performed with $^{111}$In-pentetreotide, but it seems that PET using $^{68}$Ga-DOTA-TOC provides higher accuracy in selecting patients [34]. This kind of therapy has a low toxicity, mainly leucopenia and thrombocytopenia, and it can be effective in order to reduce hormone secretion and determine tumor shrinkage. Therefore, even if its efficacy seems lower in PGLs than in gastroenteropancreatic neuroendocrine tumors, it represents an alternative option for the treatment of surgically incurable PGLs [80]. In the future, the development of new somatostatin analogues with higher affinity for the different SSTR subtypes will provide a further possibility in the treatment of these neoplasms.

Finally a combined treatment with radiolabelled MIBG and radiolabelled somatostatin analogues might have a synergistic effect, and therefore it might be considered. Moreover, the combination treatment could permit the use of lower doses of both radionuclides, limiting side effects, particularly bone marrow toxicity.

External radiotherapy may be considered for treatment of inoperable PGLs and especially for palliation of painful bone metastases. During this procedure the patients need to be monitored because the radio-induced inflammation of the lesion can induce massive catecholamine secretion, thus inducing hypertensive crises [81].

9. Therapy: Antineoplastic Agents

The aim of chemotherapy is tumor size reduction and control of symptoms due to catecholamine secretion; it is usually reserved to patients with local advanced and/or metastatic disease, with unresectable lesions, resistant to treatment with radionuclide therapy [82]. Up to now, the most used and effective chemotherapeutic regimen is a combination of cyclophosphamide, vincristine, and dacarbazine (CVD), chosen for its use in treating another neuroendocrine tumor, neuroblastoma. It has been used for the first time in 1980s in a trial including 14 malignant PCC cases [83], updated recently by NIH [84] in a 22-year followup, with demonstration of a tumor regression and symptom relief in up to 50% of patients treated and no significant change of survival. Once CVD is stopped, PCCs often recur, becoming unresponsive to the same treatment. For these reasons, CVD may have a role as a neoadjuvant therapy in few cases, to make tumors surgically resectable and to control symptoms. CVD plus anthracyclines has been tested in one case with quite a good result [85]. Other chemotherapeutic regimens have been tested in other trials, but currently none has demonstrated effectiveness in malignant PCCs treatment [86].

10. Therapy: Targeted Approach

Up to now, treatment options for malignant PGLs are limited to chemotherapy and radionuclide therapy. These often provide symptomatic and biochemical control but are less effective in causing survival increase. Understanding specific molecular pathways alteration responsible for malignant PGLs development might hopefully in the future lead to multiple molecular-targeted therapy for a successful treatment. Effectiveness of these therapies is due to a cytostatic effect, as they interfere with specific molecular targets found along the oncogenic signaling pathways responsible for carcinogenesis and tumor growth. As stated above, both benign and malignant PGLs gene mutations are part of two distinct molecular pathways leading to tumorigenesis: cluster 1 includes mutations of VHL, SDHB, and SDHD and is associated to pseudohypoxia and aberrant VEGF signaling, leading to abnormal hypoxia inducible factor (HIF) activation and overexpression of angiogenic factors, while cluster 2 includes mutations of RET, NF1, TMEM127, and...
MAX and is associated with abnormal activation of kinase-signaling pathways such as PI3 kinase/AKT, RAS/RAF/ERK, and mTOR1/p70s6K, leading to abnormal cell growth and lack of apoptosis capacity. In addition, malignant PCCs seem to overexpress HSP90, a molecular chaperone that assists in folding proteins and stabilizes various oncoproteins that play a role in malignant phenotype [87, 88].

Thus, HIF1α inhibitors are molecular targeted drugs interfering with HIF hypoxia-driven transcription pathway, decreasing HIF activity directly, PX-478 (S-2-amino-3-[4′-N,N′,bis (2-chloroethyl)amino]-phenyl propionic acid N-oxidized hydrochloride), and indirectly, PX-12 (1-methylpropyl 2-imidazoyl disulfide). These agents have shown marked antitumoral activity in human tumor xenografts in mice and seem to be promising also for malignant PGLs, but conclusive data are missing [89–91].

The mTOR inhibitor everolimus (RAD001) in combination with octreotide has been evaluated for low- and intermediate-grade neuroendocrine tumors [92], with good results. The efficacy of everolimus has been evaluated also in malignant PGLs, but all patients experienced disease progression [4, 93]. Maybe the low efficacy is due to a compensatory PI3K/AKT and ERK activation in response to mTOR inhibition, so a specific novel dual PI3k/mTOR inhibitor (NVP-BEZ235) might offer a novel therapeutic approach [94]. Further studies on the PI3K/AKT/mTOR pathway have to be conducted to find a more specific molecular target in its signalling.

Due to overexpression of HSP90 in malignant PCCs [40, 95], inhibition of its pathway could represent a future therapeutic challenge for the treatment of malignant PCCs, but at present current specific drug trials are missing.

Several studies have demonstrated overexpression in malignant PCCs of angiogenic molecules, such as VEGF, its receptor, angioptietin-2, and the endothelin receptors ETA and ETB [96–100], leading a strong evidence that targeting this pathway with antiangiogenic therapies could represent a new promising treatment option. Accordingly, sunitinib, a receptor tyrosine kinase inhibitor acting on several targets (VEGF, PDGF, and c-KIT), with strong antiangiogenic and antitumor activity, has been used in the treatment of malignant PCCs, with promising results [101–104].

Imatinib, another tyrosine kinase inhibitor already used for hematologic and gastrointestinal stromal tumors, has not been found effective for malignant PCCs treatment [105].

Thalidomide, by targeting VEGF and basic fibroblast growth factor, is an antiangiogenic agent evaluated for treatment of metastatic renal cell cancer, multiple myeloma and nonsmall cell lung cancer [106, 107]. It has been used in combination with Temozolomide in neuroendocrine tumors [108] obtaining an objective biochemical response rate in about 40% and a radiologic response rate in 33% of malignant PCCs, but lymphopenia occurred in about 70% of treated patients.

Activators of prolyl hydroxylase (PHD) (such as ERBB2 inhibitors) are now on evaluation as promising antineoplastic therapies. These molecules decrease the expression levels of some angiogenic factors, such as VEGF, acting on HIF pathway, by activating the PHD, thus increasing HIF hydroxylation, and promoting its degradation [109, 110].

Treatment of malignant PGLs is up to now basically palliative. Molecular targeted therapies are promising strategies, but, due to the complexity of these tumors pathogenesis, further studies on tumor biology, discovery of novel targeted drugs, and new trials are needed to achieve more effective treatments.

11. Conclusions

Malignant PGLs, as defined by the presence of metastases, are very rare and aggressive tumors. Their study is made difficult by their rarity, and the consequent limited number of patients included in the series, by their biological variability, by their variable genetic background, and by the lack of specific and sensitive histopathological or biological markers proving malignancy. Therefore, as benign tumors are diagnosed by the lack of metastases, and as metastatic spread can occur also several years after surgical removal of primary tumor, studies comparing benign and malignant PGLs need a long clinical followup of patients.

Large collaborative international studies, as those presently conducted on behalf of the European Network for the Study of Adrenal Tumors (ENS@T), are needed to improve our knowledge on the pathogenesis of these malignant tumors and to achieve a satisfactory medical treatment for affected patients.

Acknowledgments

This work has been partly supported by Fondazione Cassa di Risparmio di Pistoia e Pescia Prot. 2010.0278. Gabriele Parenti, Benedetta Zampetti, Elena Rapizzi, Tonino Ercolino, and Massimo Mannelli are members of the European Network for the Study of Adrenal Tumors (ENS@T).

References

[1] J. W. M. Lenders, G. Eisenhofer, M. Mannelli, and K. Pacak, “Phaeochromocytoma,” Lancet, vol. 366, no. 9486, pp. 663–675, 2005.

[2] K. Pacak, G. Eisenhofer, H. Ahlman et al., “Pheochromocytoma: recommendations for clinical practice from the First International Symposium,” Nature Clinical Practice Endocrinology and Metabolism, vol. 3, no. 2, pp. 92–102, 2007.

[3] J. Welander, P. Söderkvist, and O. Gimm, “Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas,” Endocrine-Related Cancer, vol. 18, no. 6, pp. R253–R276, 2011.

[4] A. Chрисoulidou, G. Kaltzas, I. Ilias, and A. B. Grossman, “The diagnosis and management of malignant phaeochromocytoma and paraganglioma,” Endocrine-Related Cancer, vol. 14, no. 3, pp. 569–585, 2007.

[5] J. H. Lee, F. Barich, L. H. Karnell et al., “National cancer data base report on malignant paragangliomas of the head and neck,” Cancer, vol. 94, no. 3, pp. 730–737, 2002.

[6] M. Mannelli, L. Ianni, A. Cilotti, and A. Conti, “Phaeochromocytoma in Italy: a multicentric retrospective study,”
Elevated serum neuron-specific enolase

E. van der Harst, W. W. de Herder, R. R. de Krijger et al., "High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing," Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 6, pp. 2175–2185, 1998.

The value of plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.

The plasma markers for the clinical behaviour of pheochromocytomas," European Journal of Endocrinology, vol. 147, no. 1, pp. 85–94, 2002.
| Reference                                                                 | Title                                                                 | Journal                                                                 |
|--------------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------|
| [36] R. I. Linnoila, H. R. Keiser, S. M. Steinberg, and E. E. Lack,        | "Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features," | *Human Pathology*, vol. 21, no. 11, pp. 1168–1180, 1990.               |
| [37] N. Kimura, T. Watanabe, T. Noshiro, S. Shizawa, and Y. Miura,        | "Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors," | *Endocrine Pathology*, vol. 16, no. 1, pp. 23–32, 2005.                |
| [38] L. D. R. Thompson,                                                  | "Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases," | *American Journal of Surgical Pathology*, vol. 26, no. 5, pp. 551–566, 2002. |
| [39] V. E. Strong, T. Kennedy, H. Al-Ahmadi et al.,                     | "Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis," | *Surgery*, vol. 143, no. 6, pp. 759–768, 2008.                        |
| [40] C. Boltze, J. Mundschken, N. Unger et al.,                         | "Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma," | *Journal of Clinical Endocrinology and Metabolism*, vol. 88, no. 9, pp. 4280–4286, 2003. |
| [41] T. H. Liu, Y. J. Chen, S. F. Wu et al.,                            | "Distinction between benign and malignant pheochromocytoma,"          | *Zhonghua Bing Li Xue Za Zhi*, vol. 33, no. 3, pp. 198–202, 2004.       |
| [42] V. Häyry, K. Salmekivi, J. Arola, P. Heikkilä, C. Haglund, and H.   | "High frequency of SNAIL-expressing cells confirms and predicts metastatic potential of pheochromocytoma," | *Endocrine-Related Cancer*, vol. 16, no. 4, pp. 1211–1218, 2009.        |
| [43] J. Waldmann, E. P. Slater, P. Langer et al.,                       | "Expression of the transcription factor Snail and its target gene Twist are associated with malignancy in pheochromocytomas," | *Annals of Surgical Oncology*, vol. 16, no. 7, pp. 1997–2005, 2009.    |
| [44] B. M. Engels and G. Hutvagner,                                     | "Principles and effects of microRNA-mediated post-transcriptional gene regulation," | *Oncogene*, vol. 25, no. 46, pp. 6163–6169, 2006.                      |
| [45] G. Y. Meyer-Rochow, N. E. Jackson, J. V. Conaglen et al.,          | "MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets," | *Endocrine-Related Cancer*, vol. 17, no. 3, pp. 835–840, 2010.          |
| [46] E. Latif, K. Torny, J. Gnarra et al.,                              | "Identification of the von Hippel-Lindau disease tumor suppressor gene," | *Science*, vol. 260, no. 5112, pp. 1317–1320, 1993.                    |
| [47] M. M. Walther, R. Reiter, H. R. Keiser et al.,                     | "Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma," | *Journal of Urology*, vol. 162, no. 3 I, pp. 659–664, 1999.            |
| [48] H. P. H. Neumann, D. P. Berger, G. Sigmund et al.,                 | "Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease," | *New England Journal of Medicine*, vol. 329, no. 21, pp. 1531–1538, 1993. |
| [49] H. P. H. Neumann, D. P. Berger, G. Sigmund et al.,                 | "Erratum: pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease," | *New England Journal of Medicine*, vol. 331, no. 22, p. 1335, 1994.       |
| [50] C. Eng, D. P. Smith, L. M. Mulligan et al.,                        | "Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours," | *Human Molecular Genetics*, vol. 3, no. 2, pp. 237–241, 1994.            |
| [51] C. Eng, D. P. Smith, L. M. Mulligan et al.,                        | "Erratum: point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours," | *Human Molecular Genetics*, vol. 3, no. 4, p. 686, 1994.                |
| [52] C. Eng,                                                          | "Seminars in medicine of the Beth Israel Hospital, Boston: the RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease," | *New England Journal of Medicine*, vol. 335, no. 13, pp. 943–951, 1996. |
| [53] R. White and P. O'Connell,                                        | "Identification and characterization of the gene for neurofibromatosis type 1," | *Current Opinion in Genetics and Development*, vol. 1, no. 1, pp. 15–19, 1991. |
| [54] H. P. H. Neumann, B. Bausch, S. R. McWhinney et al.,               | "Germ-line mutations in nonsyndromic pheochromocytoma," | *New England Journal of Medicine*, vol. 346, no. 19, pp. 1459–1466, 2002. |
| [55] B. E. Baysal, R. E. Ferrell, J. E. Willett-Brozek et al.,          | "Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma," | *Science*, vol. 287, no. 5454, pp. 848–851, 2000.                      |
| [56] S. Niemann and U. Muller,                                          | "Mutations in SDHC cause autosomal dominant paraganglioma, type 3," | *Nature Genetics*, vol. 26, no. 3, pp. 268–270, 2000.                    |
| [57] D. Astuti, F. Latif, A. Dallo et al.,                              | "Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma," | *American Journal of Human Genetics*, vol. 69, no. 1, pp. 49–54, 2001. |
| [58] N. Burnichon, J. J. Brière, R. Libé et al.,                       | "SDHA is a tumor suppressor gene causing paraganglioma," | *Human Molecular Genetics*, vol. 19, no. 15, pp. 3011–3020, 2010.        |
| [59] H. X. Hao, O. Khalimonchuk, M. Schraders et al.,                  | "SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma," | *Science*, vol. 325, no. 5944, pp. 1139–1142, 2009.                    |
| [60] Y. Qin, L. Yao, E. E. King et al.,                                 | "Germline mutations in TMEM127 confer susceptibility to pheochromocytoma," | *Nature Genetics*, vol. 42, no. 3, pp. 229–233, 2010.                   |
| [61] I. Comino-Méndez, F. J. Gracia-Aznárez, F. Schiavi et al.,         | "Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma," | *Nature Genetics*, vol. 43, no. 7, pp. 663–667, 2011.                    |
| [62] A. P. Gimenez-Roqueplo, J. Favori, P. Rustin et al.,               | "Mutations in the SDHB gene are associated with extra-adrenal and/or malignant pheochromocytomas," | *Cancer Research*, vol. 63, no. 17, pp. 5615–5621, 2003.                |
| [63] M. Mannelli, M. Castellano, F. Schiavi et al.,                     | "Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas," | *Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 5, pp. 1541–1547, 2009. |
| [64] P. L. M. Dahia, K. N. Ross, M. E. Wright et al.,                   | "A Hif1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas," | *PLoS Genetics*, vol. 1, no. 1, pp. 72–80, 2005.                        |
| [65] J. Favori, J. J. Brière, N. Burnichon et al.,                      | "The Warburg effect is genetically determined in inherited pheochromocytomas," | *PLoS One*, vol. 4, no. 9, Article ID e7094, 2009.                      |
[66] D. Califano, C. Rizzo, A. D’Alessio et al., “Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells,” Journal of Biological Chemistry, vol. 275, no. 25, pp. 19297–19305, 2000.

[67] G. A. Martin, D. Viskochil, G. Bollag et al., “The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21,” Cell, vol. 63, no. 4, pp. 843–849, 1990.

[68] C. M. Johannessen, E. E. Reczek, M. F. James, H. Brems, E. Legius, and K. Cichowski, “The NF1 tumor suppressor critically regulates TSC2 and mTOR,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 24, pp. 8573–8578, 2005.

[69] C. M. Johannessen, B. W. Johnson, S. G. Williams et al., “The GAP-interacting domain of the Ras p21 GTPase is essential for Ras signalling,” Current Biology, vol. 18, no. 1, pp. 56–62, 2008.

[70] M. Brauckhoff, O. Gimm, and H. Dralle, “Preoperative and surgical therapy in sporadic and familial pheochromocytoma. H. Lehner Eds.: Phaeochromocytoma, Pathophysiology and Clinical Management,” Frontiers of Hormone Research, vol. 31, pp. 121–144, 2004.

[71] T. Buhl, I. Mortensen, and A. Kjaer, “I-123 MIBG imaging and intraoperative localization of metastatic pheochromocytoma: a case report,” Clinical Nuclear Medicine, vol. 27, no. 3, pp. 183–185, 2002.

[72] S. K. Maithel and Y. Fong, “Hepatic ablation for neuroendocrine tumor metastases,” Journal of Surgical Oncology, vol. 100, no. 8, pp. 635–638, 2009.

[73] J. C. Sisson, B. Shapiro, and W. H. Beierwaltes, “Radiochemical treatment of malignant pheochromocytoma,” Journal of Nuclear Medicine, vol. 25, no. 2, pp. 197–206, 1984.

[74] G. A. Kaltas, J. J. Mukherjee, R. Foley, K. E. Britton, and A. B. Grossman, “Treatment of metastatic pheochromocytoma and paraganglioma with 131I-metaiodobenzylguanidine (MIBG),” Endocrinologist, vol. 13, no. 4, pp. 321–333, 2003.

[75] G. A. Kaltas, D. Papadogias, P. Makras, and A. B. Grossman, “Treatment of advanced neuroendocrine tumours with radio-labelled somatostatin analogues,” Endocrine-Related Cancer, vol. 12, no. 4, pp. 683–699, 2005.

[76] P. A. Fitzgerald, R. E. Goldsby, J. P. Huberty et al., “Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG),” Annals of New York Academy of Sciences, vol. 1073, pp. 465–470, 2006.

[77] K. C. Loh, P. A. Fitzgerald, K. K. Matthy, P. P. B. Yeo, and D. C. Price, “The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients,” Journal of Endocrinological Investigation, vol. 20, no. 11, pp. 648–658, 1997.

[78] D. J. Kweekkeboom, J. Mueller-Brand, G. Paganelli et al., “Overview of results of peptide receptor radionuclide therapy with 3 radio labeled somatostatin analogs,” Journal of Nuclear Medicine, vol. 46, no. 1, pp. 562–566, 2005.

[79] D. J. Kweekkeboom, W. W. De Herder, B. L. Kam et al., “Treatment with the radio labeled somatostatin analog [177Lu DOTA,Tyr3]octreotate: toxicity, efficacy, and survival,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2124–2130, 2008.

[80] F. Forrer, I. Kiedweg, H. R. Maacke, and J. Mueller-Brand, “Radio labeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 4, pp. 334–340, 2008.

[81] S. Teno, A. Tanabe, K. Nomura, and H. Demura, “Acutely exacerbated hypertension and increased inflammatory signs due to radiation treatment for metastatic pheochromocytoma,” Endocrine Journal, vol. 43, no. 5, pp. 511–516, 1996.

[82] K. F. Andersen, R. Altaf, A. Krarup-Hansen et al., “Malignant pheochromocytomas and paragangliomas—the importance of a multidisciplinary approach,” Cancer Treatment Reviews, vol. 37, no. 2, pp. 111–119, 2011.

[83] S. D. Averbuch, C. S. Steakley, R. C. Young et al., “Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine,” Annals of Internal Medicine, vol. 109, no. 4, pp. 267–273, 1988.

[84] H. Huang, J. Abraham, E. Hung et al., “Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients,” Cancer, vol. 113, no. 8, pp. 2020–2028, 2008.

[85] M. Nakane, S. Takahashi, I. Sekine et al., “Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline,” Annals of Oncology, vol. 14, no. 9, pp. 1449–1451, 2003.

[86] R. H. Grogan, E. J. Mitmaker, and Q. Y. Duh, “Changing paradigms in the treatment of malignant pheochromocytoma,” Cancer Control, vol. 18, no. 2, pp. 104–112, 2011.

[87] U. Banerji, “Heat shock protein 90 as a drug target: some like it hot,” Clinical Cancer Research, vol. 15, no. 1, pp. 9–14, 2009.

[88] M. V. Powers and P. Workman, “Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors,” Endocrine-Related Cancer, vol. 13, no. 1, pp. S125–S135, 2006.

[89] G. L. Semenza, “Evaluation of HIF-1 inhibitors as anticancer agents,” Drug Discovery Today, vol. 12, no. 19–20, pp. 853–859, 2007.

[90] S. Welsh, R. Williams, L. Kirkpatrick, G. Paine-Murrieta, and G. Powis, “Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α,” Molecular Cancer Therapeutics, vol. 3, no. 3, pp. 233–244, 2004.

[91] S. J. Welsh, R. R. Williams, A. Birmingham, D. J. Newman, D. L. Kirkpatrick, and G. Powis, “The thiorodoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulphide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation,” Molecular Cancer Therapeutics, vol. 2, no. 3, pp. 235–243, 2003.

[92] J. C. Yao, A. T. Phan, D. Z. Chang et al., “Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4311–4318, 2008.

[93] M. R. Druce, G. A. Kaltas, M. Fraenkel, D. J. Gross, and A. B. Grossman, “Novel and evolving therapies in the treatment of malignant pheochromocytoma: experience with the mTOR inhibitor everolimus (RAD001),” Hormone and Metabolic Research, vol. 41, no. 9, pp. 697–702, 2009.

[94] S. Nöltling and A. B. Grossman, “Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies,” Endocrine Pathology, vol. 23, no. 1, pp. 21–33, 2012.

[95] C. Bölze, H. Lehner, R. Schneider-Stock, B. Peters, C. Huang-Vu, and A. Roessner, “HSP90 is a key for telomerase activation and malignant transition in pheochromocytoma,” Endocrine, vol. 22, no. 3, pp. 193–201, 2003.

[96] K. Salmenvi, P. Heikkilä, J. Liu, C. Haglund, and J. Arola, “VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome,” APMS, vol. 111, no. 4, pp. 458–464, 2003.
A. Zielke, M. Middeke, S. Hoffmann et al., “VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors,” Surgery, vol. 132, no. 6, pp. 1056–1063, 2002.

J. Favier, P. F. Plouin, P. Corvol, and J. M. Gasc, “Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors,” American Journal of Pathology, vol. 161, no. 4, pp. 1235–1246, 2002.

K. Kolomecki, H. Stepien, M. Bartos, and K. Kuzdak, “Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours,” Endocrine Regulations, vol. 35, no. 1, pp. 9–16, 2001.

K. Takekoshi, K. Isobe, T. Yashiro et al., “Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas,” Life Sciences, vol. 74, no. 7, pp. 863–871, 2004.

C. Jimenez, M. E. Cabanillas, L. Santarpia et al., “Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 2, pp. 386–391, 2009.

A. M. Jossha, S. Ezzat, S. L. Asa et al., “Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 1, pp. 5–9, 2009.

K. S. Park, J. L. Lee, H. Ahn et al., “Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma,” Japanese Journal of Clinical Oncology, vol. 39, no. 5, pp. 327–331, 2009.

N. M. Hahn, M. Reckova, L. Cheng, L. A. Baldridge, O. W. Cummings, and C. J. Sweeney, “Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate,” Journal of Clinical Oncology, vol. 27, no. 3, pp. 460–463, 2009.

D. J. Gross, G. Munter, M. Bitan et al., “The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 535–540, 2006.

S. Singhal, J. Mehta, R. Desikan et al., “Antitumor activity of thalidomide in refractory multiple myeloma,” New England Journal of Medicine, vol. 341, no. 21, pp. 1565–1571, 1999.

J. A. Sparano, R. Gray, B. Giaintonio, P. O’Dwyer, and R. L. Comis, “Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology group portfolio of clinical trials,” Clinical Cancer Research, vol. 10, no. 4, pp. 1206–1211, 2004.

M. H. Kulke, K. Stuart, P. C. Enzinger et al., “Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 401–406, 2006.

H. J. Choi, B. J. Song, Y. D. Gong, W. J. Gwak, and Y. Soh, “Rapid degradation of hypoxia-inducible factor-1a by KRH102053, a new activator of prolyl hydroxylase 2,” British Journal of Pharmacology, vol. 154, no. 1, pp. 114–125, 2008.

E. Temes, S. Martin-Puig, B. Acosta-Iborra et al., “Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the dicylglycerol kinase,” Journal of Biological Chemistry, vol. 280, no. 25, pp. 24238–24244, 2005.